We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




No Evidence Gadolinium Causes Neurologic Harm

By MedImaging International staff writers
Posted on 20 Dec 2017
Print article
A new study concludes there is no evidence that accumulation in the brain of the element Gadolinium (Gd) speeds cognitive decline.

Researchers at the Mayo Clinic (Rochester, MN, USA) conducted a retrospective study of the Mayo Clinic Study of Aging (MCSA) cohort in order to examine the effects of Gd exposure on neurologic and neurocognitive function. The study included 4,261 cognitively normal participants (mean age 71.9 years) who received one or more gadolinium based contrast agent (GBCA) doses. The mean time from first Gd exposure was 5.6 years. All participants underwent neurologic evaluation and neuropsychological assessment at baseline and at 15-month follow-up intervals.

After adjusting for age, sex, education level, baseline neurocognitive performance, Charlson comorbidity index, and ApoE4 status, the results showed that GBCA exposure was not a major predictor of cognitive decline, diminished neuropsychological performance, or diminished motor performance. Dose-related effects were not observed among these metrics, and Gd exposure was not an independent risk factor in the rate of cognitive decline from normal cognitive status to dementia. The study was presented at the annual meeting of the Radiological Society of North America (RSNA), held during November 2017 in Chicago (IL, USA).

“Gadolinium contrast material is used in 40-50% of MRI scans performed today; it's estimated that approximately 400 million doses of gadolinium have been administered since 1988,” said lead author neuroradiologist Robert McDonald, MD, PhD. “Right now there is concern over the safety of gadolinium-based contrast agents, particularly relating to gadolinium retention in the brain and other tissues. This study provides useful data that at the reasonable doses 95% of the population is likely to receive in their lifetime, there is no evidence at this point that gadolinium retention in the brain is associated with adverse clinical outcomes.”

Gadolinium--a rare earth heavy metal--is used for enhancement during MRI. Neurotoxic effects have been seen in animals and when a GBCA is given intrathecally in humans. On its own, gadolinium can be toxic; therefore, when used in contrast agents, gadolinium is bonded with a molecule called a chelating agent, which controls the distribution of gadolinium within the body. In July 2015, the U.S. Food and Drug Administration (FDA) stated that it was unknown whether gadolinium deposits in the brain were harmful.

Related Links:
Mayo Clinic

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Oncology Information System
RayCare
New
Portable X-Ray Unit
AJEX240H
New
Wireless Handheld Ultrasound System
TE Air

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.